Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment

• Status: Completed
• Trial end date: 2018-03-04
• Target enrollment: 0
• Participant gender: All

Summary

Assess the pharmacokinetics, safety, and tolerability of a single dose of BMS-986177 in participants with normal renal function and moderate to severe renal impairment.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Participants in Groups B and C will be classified by renal function by eGRF at screening and confirmed on Day -1

• Participants in Group A will be healthy participants as determined by no significant deviations in normal medical and surgical history and assessments

• Participants in Group A must have a body mass index of 18.0 to 32.0 kg/m2, inclusive

• Females must be of non-childbearing potential

Exclusion Criteria:

• Participants in Groups B and C cannot have an indwelling catheter for hemodialysis

• Participants in Groups B and C cannot have had, nor be waiting for, an organ transplant

Other protocol defined inclusion and exclusion criteria could apply